Replimune appoints Chris Sarchi as CCO and Sushil Patel as Chief Strategy Officer, effective immediately

Replimune Group, Inc.

Chris Sarchi, former Sanofi U.S. Commercial Oncology Head, named Chief Commercial Officer.
Sushil Patel, previously CCO, transitions to newly created Chief Strategy Officer role.
Appointments aim to ramp up commercial planning ahead of potential 2024 launch of RP1.
Sarchi led Libtayo launch in CSCC; Patel will lead ex-U.S. strategy and platform planning.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.